Skyrizi approved for ulcerative colitis

FDA has approved risankizumab-rzaa (Skyrizi) for adults with moderately to severely active ulcerative colitis. According to a manufacturer press release, approval was supported by data from two phase 3 clinical trials: a 12-week induction study (INSPIRE) and a 52-week maintenance study (COMMAND). Risankizumab is the first IL-23 antagonist approved for both ulcerative colitis and Crohn disease.